Home > Riviste > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Fascicoli precedenti > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2019 June;63(2) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2019 June;63(2):129-35

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo

 

REVIEW  BONE METASTASES IN THE ERA OF TARGETED TREATMENTS 

The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2019 June;63(2):129-35

DOI: 10.23736/S1824-4785.19.03204-7

Copyright © 2019 EDIZIONI MINERVA MEDICA

lingua: Inglese

Quantitative radionuclide imaging of bone metastases

Stijn DE SCHEPPER 1, Philipp RITT 2, Tim Van den WYNGAERT 1, 3, Torsten KUWERT 2

1 Department of Nuclear Medicine, Antwerp University Hospital, Edegem, Belgium; 2 Clinic of Nuclear Medicine, University-Hospital Erlangen-Nürnberg, Erlangen, Germany; 3 Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk, Belgium



By improving the localization of foci of pathological tracer uptake and offering information on their computed tomography (CT) morphology, single photon emission computed tomography (SPECT)/CT hybrid imaging has considerably improved the diagnostic accuracy of skeletal scintigraphy. SPECT/CT also has the potential to measure tracer uptake in vivo in absolute units. The present article reviews the methodology for and the potential clinical impact of quantitative skeletal scintigraphy.


KEY WORDS: Tomography, emission-computed, single-photon; Tomography, X-ray Computed; Physics; Radionuclide imaging

inizio pagina